QFR-Guided PCI Delivered a Clearer 3-Year Advantage in Multivessel Disease
The separation between physiology-guided and angiography-guided coronary intervention widened over time in patients with multivessel disease. In a prespecified secondary analysis of the FAVOR III China randomized clinical trial, quantitative flow ratio-guided PCI was associated with fewer 3-year major adverse cardiac events than angiography-guided PCI among patients with disease in at least 2 epicardial vessels or the left main coronary artery. The signal was not subtle: event rates were 12.1% with QFR guidance and 18.1% with angiography guidance in the multivessel cohort.
The trial enrolled adults undergoing PCI for stable angina, unstable angina, or myocardial infarction that had occurred at least 72 hours before screening. Eligible lesions had 50% to 90% diameter stenosis in a vessel measuring at least 2.5 mm. Across 26 centers in China, 3825 patients entered the intention-to-treat population, and the mean age was 62.7 years. Men accounted for 70.6% of the cohort. More than half of the population, 2066 patients, had multivessel disease, making this subgroup central to the analysis rather than a minor add-on.
The physiology-guided approach matters most when angiography becomes an unreliable shorthand for ischemic burden. In multivessel coronary disease, the eye can overestimate the importance of lesions that look narrow but are not flow limiting, while underestimating diffuse or serial disease that creates ischemia without dramatic luminal compromise. QFR attempts to correct for that mismatch by estimating coronary physiology from angiographic images, helping operators decide which stenoses deserve stenting and which can be left alone.
Event Reduction Concentrated in the Anatomically Complex Group
In the multivessel cohort, MACE occurred in 124 of 1023 patients in the QFR-guided group and 188 of 1043 patients in the angiography-guided group. The hazard ratio was 0.65, with a 95% confidence interval of 0.52 to 0.81. That degree of separation over 3 years suggests more than a procedural refinement; it points to better lesion selection at the time of PCI, fewer unnecessary stents, and a lower chance of residual ischemic burden after intervention.
A second clinical reality sits underneath those numbers. Multivessel disease exposes patients to both competing ischemic territories and the cumulative hazard of additional revascularization decisions. When the first procedure leaves behind physiologically significant lesions, downstream events become more likely. If the first procedure treats lesions that are not truly responsible for ischemia, the patient is exposed to stent-related risk without a corresponding physiologic gain. QFR-guided PCI is designed to reduce both problems at once.
The analysis was prespecified, which strengthens the credibility of the subgroup comparison. Even so, it remains a secondary analysis of a randomized trial, and the inference should stay anchored to the study frame: this is not a new trial with a different population, but a deeper look at whether anatomy modifies the benefit of physiology-guided revascularization. The cohort was screened between December 25, 2018, and January 19, 2020, and the primary analyses for this secondary report were completed in October 2024.
Why Physiology May Matter More When Disease Is Widespread
In single-vessel disease, angiography and physiology can sometimes point in the same direction. In multivessel disease, they often do not. Coronary lesions may appear comparably severe across multiple vessels, yet only some create a meaningful pressure drop during flow. QFR uses angiographic images to estimate flow limitation without the need for a pressure wire, which makes physiology more accessible at the bedside and may encourage broader use during complex PCI.
The biological rationale is straightforward. Coronary events do not arise from stenosis diameter alone; they arise from the interaction of ischemic burden, plaque biology, and the hemodynamic consequences of incomplete revascularization. By filtering out lesions that are not truly flow limiting, physiology-guided PCI may reduce the number of stents implanted, the metal burden left behind, and the likelihood that an untreated lesion later drives recurrent angina or another procedure. In a patient with multivessel disease, that can translate into fewer opportunities for future ischemic episodes to accumulate.
One sentence captures the clinical meaning of the result: physiology-guided selection beat anatomy alone when coronary disease involved multiple vessels.
What the 3-Year Signal Means for the Cath Lab
The trial’s original primary end point was 1-year MACE, defined as a composite of all-cause death, myocardial infarction, and ischemia-driven revascularization. The present analysis extends the observation window to 3 years, where the consequences of initial lesion selection become easier to see. Revascularization strategy is rarely judged by the angiographic result alone; the relevant question is whether the patient spends the next several years with fewer infarctions, fewer repeat procedures, and less ischemia-related instability.
For operators, the practical implication is familiar but important. In multivessel disease, angiography can guide where to look, but physiology helps determine where to act. QFR offers a way to incorporate physiologic information without the extra procedural burden of wire-based measurements, and that matters in real-world PCI workflows where speed, safety, and completeness of assessment often compete.
The subgroup findings do not rewrite coronary care, and they should not be stretched beyond the enrolled population. Participants were drawn from centers in China, lesions were limited by diameter and stenosis criteria, and the comparison was anchored to a specific trial protocol. Still, the direction of effect is clinically coherent: the more complex the coronary anatomy, the more room there is for physiology to improve lesion targeting and long-term outcomes.
Residual Questions After the Secondary Analysis
The report leaves several practical questions open. The analysis does not answer whether the same magnitude of benefit would appear in different health systems, in populations with different baseline risk, or in centers with lower familiarity with physiology-guided PCI. It also does not establish whether every form of multivessel disease should automatically trigger QFR-based planning; lesion morphology, clinical presentation, and operator judgment remain part of the decision.
What this study does show is narrower and more useful. In a large randomized cohort, patients with multivessel disease had fewer 3-year major adverse cardiac events when PCI was guided by QFR rather than angiography alone. For interventional cardiology, that is a strong argument for treating coronary anatomy as a starting point, not the final word, when the disease burden extends beyond a single vessel.